{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:24:04Z","timestamp":1787387044163,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12325-026-03628-x","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:52:30Z","timestamp":1781081550000},"page":"4008-4022","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Integrated Safety and Efficacy of Garadacimab for Hereditary Angioedema Prophylaxis"],"prefix":"10.1007","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct03712228","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04656418","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04739059","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7774-4855","authenticated-orcid":false,"given":"Timothy J.","family":"Craig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7242-9584","authenticated-orcid":false,"given":"Mar","family":"Guilarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5587-968X","authenticated-orcid":false,"given":"Huamin Henry","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3578-8064","authenticated-orcid":false,"given":"John","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Martinez Saguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua S.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5387-0013","authenticated-orcid":false,"given":"Raffi","family":"Tachdjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2929-1721","authenticated-orcid":false,"given":"Henriette","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Ohsawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1930-4755","authenticated-orcid":false,"given":"Roman","family":"Hakl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maressa","family":"Pollen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1259-5422","authenticated-orcid":false,"given":"Ingo","family":"Pragst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John-Philip","family":"Lawo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsha","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Nenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9218-5468","authenticated-orcid":false,"given":"Markus","family":"Magerl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"1","key":"3628_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","volume":"9","author":"PJ Busse","year":"2021","unstructured":"Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA medical advisory board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132\u201350.e3.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"3628_CR2","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/all.15214","volume":"77","author":"M Maurer","year":"2022","unstructured":"Maurer M, Magerl M, Betschel S, et al. The international WAO\/EAACI guideline for the management of hereditary angioedema\u2013the 2021 revision and update. Allergy. 2022;77(7):1961\u201390.","journal-title":"Allergy"},{"issue":"Suppl 1","key":"3628_CR3","doi-asserted-by":"publisher","first-page":"S08","DOI":"10.2500\/aap.2020.41.200050","volume":"41","author":"WR Lumry","year":"2020","unstructured":"Lumry WR, Settipane RA. Hereditary angioedema: epidemiology and burden of disease. Allergy Asthma Proc. 2020;41(Suppl 1):S08\u2013S13.","journal-title":"Allergy Asthma Proc"},{"issue":"2","key":"3628_CR4","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jaci.2024.03.024","volume":"154","author":"A Reshef","year":"2024","unstructured":"Reshef A, Buttgereit T, Betschel SD, et al. Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus. J Allergy Clin Immunol. 2024;154(2):398\u2013411.e1.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"3628_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jaci.2016.02.041","volume":"138","author":"ZL Hofman","year":"2016","unstructured":"Hofman ZL, Relan A, Zeerleder S, Drouet C, Zuraw B, Hack CE. Angioedema attacks in patients with hereditary angioedema: local manifestations of a systemic activation process. J Allergy Clin Immunol. 2016;138(2):359\u201366.","journal-title":"J Allergy Clin Immunol"},{"issue":"18","key":"3628_CR6","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1182\/blood.2022015610","volume":"139","author":"AP Kaplan","year":"2022","unstructured":"Kaplan AP. Bradykinin formation by mutant plasminogen. Blood. 2022;139(18):2732\u20133.","journal-title":"Blood"},{"issue":"2","key":"3628_CR7","first-page":"82","volume":"38","author":"A Lopez Lera","year":"2021","unstructured":"Lopez Lera A. Pathophysiology and underlying mechanisms in hereditary angioedema. Balkan Med J. 2021;38(2):82\u20138.","journal-title":"Balkan Med J"},{"issue":"3","key":"3628_CR8","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.iac.2017.03.003","volume":"37","author":"M Chen","year":"2017","unstructured":"Chen M, Riedl MA. Emerging therapies in hereditary angioedema. Immunol Allergy Clin North Am. 2017;37(3):585\u201395.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"4","key":"3628_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/joim.20008","volume":"296","author":"DM Cohn","year":"2024","unstructured":"Cohn DM, Renne T. Targeting factor\u00a0XIIa for therapeutic interference with hereditary angioedema. J Intern Med. 2024;296(4):311\u201326.","journal-title":"J Intern Med"},{"issue":"7","key":"3628_CR10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/14712598.2025.2512128","volume":"25","author":"JKY Hooi","year":"2025","unstructured":"Hooi JKY, Wong JCY, Li PH. The potential of factor\u00a0XII inhibitors in preventing hereditary angioedema attacks. Expert Opin Biol Ther. 2025;25(7):703\u201310.","journal-title":"Expert Opin Biol Ther"},{"key":"3628_CR11","unstructured":"ANDEMBRY TGA. ANDEMBRY\u00ae (garadacimab) Australian Summary of Product Characteristics. CSL Behring (Australia) Pty Ltd, Broadmeadows VIC, Australia. 2025. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent=&id=CP-2025-PI-01056-1&d=20250502172310101. Accessed 16 Oct 2025."},{"key":"3628_CR12","unstructured":"ANDEMBRY EMA. ANDEMBRY\u00ae (garadacimab) EU Summary of Product Characteristics. CSL Behring GmBH, Marburg, Germany. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/andembry-epar-product-information_en.pdf. Accessed 16 Oct 2025."},{"key":"3628_CR13","unstructured":"ANDEMBRY Japan. ANDEMBRY\u00ae (garadacimab) PMDA Product Information. CSL Behring K.K., Tokyo, Japan. 2025. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/100806_4490411G1020_1_01. Accessed 16 Oct 2025."},{"key":"3628_CR14","unstructured":"ANDEMBRY Switzerland. ANDEMBRY\u00ae (garadacimab) Swiss Public Assessment Report 2025. CSL Behring AG, Bern, Switzerland. 2025. https:\/\/www.swissmedic.ch\/dam\/swissmedic\/en\/dokumente\/zulassung\/swisspar\/69553-andembry-01-swisspar-20250404.pdf.download.pdf\/SwissPAR_Andembry.pdf. Accessed 16 Oct 2025."},{"key":"3628_CR15","unstructured":"ANDEMBRY MHRA. ANDEMBRY\u00ae (garadacimab) P200\u00a0mg solution for injection in a pre-filled syringe. MHRA UK Summary of Product Characteristics. CSL Behring GmbH, Marburg, Germany. 2025. https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/357da948fcc3f4ef9543a1fb0699cdfc3182ef68. Accessed 16 Oct 2025."},{"key":"3628_CR16","unstructured":"ANDEMBRY MHRA. ANDEMBRY\u00ae (garadacimab) 200\u00a0mg solution for injection in a pre-filled pen. CSL Behring GmbH, Marburg, Germany. 2025. https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/f1cf7f4ee09a120298ae6e9ed379b80fb360defc. Accessed 16 Oct 2025."},{"key":"3628_CR17","unstructured":"ANDEMBRY FDA. ANDEMBRY\u00ae (garadacimab-gxii) injection, for subcutaneous use initial U.S. approval, CSL Behring LLC King of Prussia, PA. 2025. https:\/\/labeling.cslbehring.com\/PI\/US\/Andembry\/EN\/Andembry-Prescribing-Information.pdf. Accessed 16 Oct 2025."},{"key":"3628_CR18","unstructured":"CSL Newsroom. U.S. Food and Drug Administration approves CSL's ANDEMBRY\u00ae (garadacimab-gxii), the only prophylactic hereditary angioedema (HAE) treatment targeting factor\u00a0XIIa with once-monthly dosing for all patients from the start. 2025. https:\/\/newsroom.csl.com\/2025-06-16-U-S-Food-and-Drug-Administration-Approves-CSLs-ANDEMBRY-R-garadacimab-gxii-,-the-Only-Prophylactic-Hereditary-Angioedema-HAE-Treatment-Targeting-Factor-XIIa-with-Once-Monthly-Dosing-for-All-Patients-From-the-Start. Accessed 16 Oct 2025."},{"issue":"10328","key":"3628_CR19","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0140-6736(21)02225-X","volume":"399","author":"T Craig","year":"2022","unstructured":"Craig T, Magerl M, Levy DS, et al. Prophylactic use of an anti-activated factor\u00a0XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase\u00a02 trial. Lancet. 2022;399(10328):945\u201355.","journal-title":"Lancet"},{"issue":"6","key":"3628_CR20","doi-asserted-by":"publisher","first-page":"e436","DOI":"10.1016\/S2352-3026(24)00081-4","volume":"11","author":"TJ Craig","year":"2024","unstructured":"Craig TJ, Levy DS, Reshef A, et al. Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase\u00a02, randomised, open-label extension study. Lancet Haematol. 2024;11(6):e436\u201347.","journal-title":"Lancet Haematol"},{"issue":"10382","key":"3628_CR21","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0140-6736(23)00350-1","volume":"401","author":"TJ Craig","year":"2023","unstructured":"Craig TJ, Reshef A, Li HH, et al. Efficacy and safety of garadacimab, a factor\u00a0XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet. 2023;401(10382):1079\u201390.","journal-title":"Lancet"},{"issue":"2","key":"3628_CR22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/all.16351","volume":"80","author":"A Reshef","year":"2025","unstructured":"Reshef A, Hsu C, Katelaris CH, et al. Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: phase\u00a03 open-label extension study. Allergy. 2025;80(2):545\u201356.","journal-title":"Allergy"},{"key":"3628_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.08.005","author":"DM Cohn","year":"2025","unstructured":"Cohn DM, Reshef A, Staubach P, et al. Garadacimab in hereditary angioedema due to normal C1INH with F12\/PLG mutations. J Allergy Clin Immunol. 2025. https:\/\/doi.org\/10.1016\/j.jaci.2025.08.005.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"3628_CR24","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1111\/cea.14568","volume":"54","author":"P Staubach","year":"2024","unstructured":"Staubach P, Tachdjian R, Li HH, et al. Timing of onset of garadacimab for preventing hereditary angioedema attacks. Clin Exp Allergy. 2024;54(12):1020\u20133.","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"3628_CR25","volume":"10","author":"HD Fernandes","year":"2018","unstructured":"Fernandes HD, Newton S, Rodrigues JM. Factor\u00a0XII deficiency mimicking bleeding diathesis: a unique presentation and diagnostic pitfall. Cureus. 2018;10(6):e2817.","journal-title":"Cureus"},{"issue":"2","key":"3628_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1055\/s-0038-1647467","volume":"65","author":"B Lammle","year":"1991","unstructured":"Lammle B, Wuillemin WA, Huber I, et al. Thromboembolism and bleeding tendency in congenital factor\u00a0XII deficiency\u2014a study on 74 subjects from 14 Swiss families. Thromb Haemost. 1991;65(2):117\u201321.","journal-title":"Thromb Haemost"},{"issue":"22","key":"3628_CR27","doi-asserted-by":"publisher","first-page":"4296","DOI":"10.1182\/blood-2012-07-292094","volume":"120","author":"T Renne","year":"2012","unstructured":"Renne T, Schmaier AH, Nickel KF, Blomback M, Maas C. In vivo roles of factor\u00a0XII. Blood. 2012;120(22):4296\u2013303.","journal-title":"Blood"},{"key":"3628_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.70099","author":"F Glassman","year":"2025","unstructured":"Glassman F, Lawo JP, Bica MA, et al. A phase\u00a01 randomized study: garadacimab pharmacokinetics, safety, and tolerability after administration via autoinjector\/pre-filled pen versus pre-filled syringe in healthy participants. J Clin Pharmacol. 2025. https:\/\/doi.org\/10.1002\/jcph.70099.","journal-title":"J Clin Pharmacol"},{"key":"3628_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-019-0362-1","volume":"15","author":"HH Li","year":"2019","unstructured":"Li HH, et al. Association between methylation in nasal epithelial TSLP gene and chronic rhinosinusitis with nasal polyps. Allergy Asthma Clin Immunol. 2019;15:49.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"3628_CR30","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1111\/cea.13974","volume":"51","author":"DT Johnston","year":"2021","unstructured":"Johnston DT, et al. Effectiveness of lanadelumab for preventing hereditary angioedema attacks: subgroup analyses from the HELP study. Clin Exp Allergy. 2021;51:1391\u20135.","journal-title":"Clin Exp Allergy"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03628-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03628-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03628-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:04:29Z","timestamp":1787385869000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03628-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3628"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03628-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Timothy J. Craig is a speaker for CSL Behring, Grifols, KalVista Pharmaceuticals, and Takeda Pharmaceuticals; has received research and consultancy grants from Astria Therapeutics, BioCryst, BioMarin Pharmaceutical, CSL Behring, Grifols, Ionis Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, and Takeda Pharmaceuticals; and is on the Medical Advisory Board for the US Hereditary Angioedema Association and Director of ACARE Angioedema Center at Penn State University, Hershey, PA, USA. Timothy Craig is an Editorial Board member of\n                      Advances in Therapy\n                      . Timothy Craig was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Mar Guilarte has received honoraria for educational purposes from CSL Behring, Novartis, and Takeda Pharmaceuticals; has participated in advisory boards organized by CSL Behring, Novartis, and Takeda Pharmaceuticals; and has received funding to attend conferences and educational events from CSL Behring, Novartis, Pharming Group, and Takeda Pharmaceuticals. She is also a clinical trial\/registry investigator for BioCryst, CSL Behring, Novartis, Pharming Group, Pharvaris, and Takeda Pharmaceuticals and a researcher from the Vall d\u2019Hebron Research Institute program for promoting research activities. Huamin Henry Li has received speaking fees for BioCryst, CSL Behring, Pharming Group, and Takeda Pharmaceuticals, and research and consultancy grants from BioCryst, BioMarin Pharmaceutical, CSL Behring, Ionis Pharmaceuticals, Pharming Group, Pharvaris, and Takeda Pharmaceuticals. John Anderson has been a speaker bureau member for BioCryst, CSL Behring, Pharming Group, and Takeda Pharmaceuticals; is a clinical trial investigator for BioCryst, BioMarin Pharmaceutical, CSL Behring, KalVista Pharmaceuticals, Pharming Group, Pharvaris, and Takeda Pharmaceuticals; and has received consulting fees from Cycle Pharma. Inmaculada Martinez Saguer has received honoraria, research funding, and travel grants from BioCryst, CSL Behring, KalVista Pharmaceuticals, Octapharma, Pharming Group, Pharvaris, and Takeda, or has served as a consultant or participated in advisory boards for these companies. Joshua S. Jacobs has received honoraria as a speaker for AstraZeneca, CSL Behring, GSK, Regeneron Pharmaceuticals, Sanofi-Genzyme, Takeda, and Teva, and has received research funding or consultancy fees from Allakos, AstraZeneca, BioCryst, CSL Behring, Fresenius Kabi, Genentech, GSK, Novartis, Regeneron Pharmaceuticals, and Takeda. Raffi Tachdjian has received speaking or consultancy fees from Astria Therapeutics, BioCryst, CSL Behring, GSK, Intellia, Ionis Pharmaceuticals, KalVista Pharmaceuticals, Lilly, Novartis, Pharming Group, Pharvaris, and Takeda Pharmaceuticals. Henriette Farkas has received research grants from CSL Behring, Pharming Group, and Takeda Pharmaceuticals; has served as an advisor for BioCryst, CSL Behring, KalVista Pharmaceuticals, ONO Pharmaceutical, Pharming Group, and Takeda Pharmaceuticals; and has participated in clinical studies or registries for BioCryst, CSL Behring, KalVista Pharmaceuticals, Pharming Group, Pharvaris, and Takeda Pharmaceuticals. William H. Yang has been a speaker and advisory board member for, and has received honoraria from, AstraZeneca, BioCryst, CSL Behring, Merck, Novartis, Sanofi-Genzyme, and Takeda. He has received research grants from Aimmune Therapeutics, ALK Abello, AnaptysBio, Areteia, Aslan, AstraZeneca, Astria Therapeutics, BioCryst, Blueprint, Bristol Myers Squibb, Celgene, Celldex Therapeutic Inc, CSL Behring, DBV Technologies, Dermira, Eli Lily, Escient, Evommune, Galderma, Genentech, GSK, Glenmark, Haleon, Incyte, Intellia Therapeutics, Ionis, Moderna, Novartis, Novavax, Pharming, Pharvaris, Providence, RAPT Therapeutics, Regeneron, Roche, Sanofi, Stallergenes, Takeda, Triveni Bio, Upstream Bio, and VBI. Isao Ohsawa has received honoraria or served as a consultant or participated in advisory boards for CSL Behring, Takeda, and Torii Pharmaceutical Company. Roman Hakl has received speaker or consultancy fees or travel grants from, or has participated in advisory boards for, CSL Behring, Pharming Group, Shire, and Takeda Pharmaceuticals; and has served as a Principal Investigator for clinical studies sponsored by BioCryst, CSL Behring, KalVista Pharmaceuticals, Pharming Group, and Pharvaris. Maressa Pollen is a full-time employee of CSL Behring LLC and a shareholder of CSL Limited. Ingo Pragst is a full-time employee of CSL Innovation GmbH and a shareholder of CSL Limited. John-Philip Lawo was a full-time employee of CSL Innovation GmbH and a shareholder of CSL Limited at the time of the study. He is now a full-time employee of Sanofi. Harsha Shetty is a full-time employee of CSL Behring LLC and a shareholder of CSL Limited. Chiara Nenci is a full-time employee of CSL Behring AG and a shareholder of CSL Limited. Markus Magerl has received financial support from CSL Behring for acting as a study center investigator during the conduct of the study and acted as an investigator in clinical studies and\/or received consulting fees from Argo, Astria, BioCryst, CSL Behring, Intellia, Ionis Pharmaceuticals\/Otsuka, KalVista Pharmaceuticals, Octapharma, Pharvaris, and Takeda outside of the submitted work.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics and consent details for the individual studies in the integrated analyses have been reported previously [\n                      \n                      ,\n                      \n                      ,\n                      \n                      ]. For all three studies, clinical trial protocols and informed consent forms were approved by institutional review boards or ethics committees. All studies were conducted in accordance with the Declaration of Helsinki and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice Guidelines.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}